Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.

NCT04602975 is registered in ClinicalTrials.gov with Institut Pasteur as lead sponsor.

NCT NCT04602975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04602975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Age Descending Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a in Adults, Children, and Infant Target Population in Endemic Countries.
Lead sponsor
Institut Pasteur
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2020
Completion date
November 15, 2023
Enrollment
248 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy